ReNeuron RNUGF Stock
ReNeuron Price Chart
ReNeuron RNUGF Financial and Trading Overview
| ReNeuron stock price | 0.0011 USD |
| Previous Close | 0.07 USD |
| Open | 0.07 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.07 - 0.07 USD |
| 52 Week Range | 0.07 - 0.45 USD |
| Volume | 3.22K USD |
| Avg. Volume | 68 USD |
| Market Cap | 5.55M USD |
| Beta (5Y Monthly) | 1.07816 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
RNUGF Valuation Measures
| Enterprise Value | -2787837 USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 10.462417 |
| Price/Book (mrq) | 0.7840909 |
| Enterprise Value/Revenue | -5.26 |
| Enterprise Value/EBITDA | 0.401 |
Trading Information
ReNeuron Stock Price History
| Beta (5Y Monthly) | 1.07816 |
| 52-Week Change | -84.44% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.45 USD |
| 52 Week Low | 0.07 USD |
| 50-Day Moving Average | 0.09 USD |
| 200-Day Moving Average | 0.16 USD |
RNUGF Share Statistics
| Avg. Volume (3 month) | 68 USD |
| Avg. Daily Volume (10-Days) | 320 USD |
| Shares Outstanding | 57.17M |
| Float | 46.27M |
| Short Ratio | N/A |
| % Held by Insiders | 19.96% |
| % Held by Institutions | 30.97% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:100 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1342.45% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -32.97% |
| Return on Equity (ttm) | -72.37% |
Income Statement
| Revenue (ttm) | 530K USD |
| Revenue Per Share (ttm) | 0.009 USD |
| Quarterly Revenue Growth (yoy) | -73.29% |
| Gross Profit (ttm) | N/A |
| EBITDA | -6945000 USD |
| Net Income Avi to Common (ttm) | -5408000 USD |
| Diluted EPS (ttm) | -0.12 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 7.15M USD |
| Total Cash Per Share (mrq) | 0.13 USD |
| Total Debt (mrq) | 421K USD |
| Total Debt/Equity (mrq) | 8.33 USD |
| Current Ratio (mrq) | 2.046 |
| Book Value Per Share (mrq) | 0.088 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -7484000 USD |
| Levered Free Cash Flow (ttm) | -6299375 USD |
Profile of ReNeuron
| Country | United States |
| State | N/A |
| City | Pencoed |
| Address | Pencoed Business Park |
| ZIP | CF35 5HY |
| Phone | 44 20 3819 8400 |
| Website | https://www.reneuron.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
ReNeuron Group plc researches, develops, and commercializes cell-based therapies in the United Kingdom. The company engages in the development of CTX stem cell therapy candidate for treating stroke disability; and human retinal progenitor cell therapy that is in Phase 2 clinical trial for treating retinitis pigmentosa, a blindness-causing disease. It also develops CTX-derived exosomes that are in the pre-clinical stage, which are Nano-sized packages of information released by CTX cells. In addition, the company licenses ReNcell products. It has a collaboration agreement with University College London to conduct research into the generation of immune cells from induced pluripotent stem cells for anti-cancer cell therapies. The company was founded in 1997 and is headquartered in Pencoed, the United Kingdom.
Q&A For ReNeuron Stock
What is a current RNUGF stock price?
ReNeuron RNUGF stock price today per share is 0.0011 USD.
How to purchase ReNeuron stock?
You can buy RNUGF shares on the Other OTC exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ReNeuron?
The stock symbol or ticker of ReNeuron is RNUGF.
Which industry does the ReNeuron company belong to?
The ReNeuron industry is Biotechnology.
How many shares does ReNeuron have in circulation?
The max supply of ReNeuron shares is 2.2B.
What is ReNeuron Price to Earnings Ratio (PE Ratio)?
ReNeuron PE Ratio is now.
What was ReNeuron earnings per share over the trailing 12 months (TTM)?
ReNeuron EPS is -0.11 USD over the trailing 12 months.
Which sector does the ReNeuron company belong to?
The ReNeuron sector is Healthcare.